On the surface, it seems like the most even prop bet one can make. But Super Bowl history says a little different.

The fair value estimate for GSK has been nudged to £18.83 from £18.73, a small move that reflects a tug of war between more optimistic price target hikes and ongoing caution around the company’s ...

The latest research on Myriad Genetics trims the modeled fair value only slightly, from US$8.32 to US$8.12 per share, and aligns a new US$7 price target with expectations across the broader ...